Shanghai Argo Biopharmaceutical Co., Ltd.
Quick facts
Phase 2 pipeline
- BW-00112
- BW-20805 · Diabetes
BW-20805 is a small molecule that acts as a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2).
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: